OBJECTIVES: Treatment outcomes improved in metastatic colorectal cancer (mCRC) due to the introduction of the monoclonal antibodies (mAb) in combination with chemotherapy. This study described current treatment patterns of chemotherapy and mAbs in clinical practice in 4 EU countries. METHODS: This cohort study used physician-surveyed data from the LifeLink TM Oncology Analyzer Database for mCRC patients in four EU countries (France, Germany, Italy, and Spain). All patients aged ≥21 years at mCRC diagnosis were included. Treatment patterns in 2009 were examined descriptively by lines of therapy. RESULTS: The study sample includes 2734 mCRC patients (61% male, median age category 61-70 years) with 862, 656, 567, and 649 from France, Germany, Italy, and Spain, respectively. In 1st-line, more patients received FOLFOX-containing regimens than FOLFIRI-containing regimens in Germany (42% vs. 30%) and Spain (25% vs. 16%), while in Italy and France, the reverse was true (Italy: 34% FOLFIRI vs. 29% FOLFOX: France: 26% vs. 19%). In 2nd-line, more patients received FOLFIRI-containing regimens than FOLFOX-containing regimens in Germany (36% vs. 18%), Italy (29% vs. 14%), and Spain (34% vs. 6%), while similar proportions of FOLFOX and FOLFIRI were used in France (18% vs. 15%). In 1st line, Bevacizumab (Bmab) was administered to 44% of patients in Italy, 42% in France, 37% in Germany, and 30% in Spain, while Cetuximab (Cmab) use ranged from 14% in Spain to 7% in Italy. In 2nd-line, Bmab was used in 37% of the patients in Germany, 38% in France, 33% in Italy, and 30% in Spain, while Cmab was used in 30% of the patients in Spain, followed by 26% in Italy, 20% in Germany and 17% in France. CONCLUSIONS: FOLFOX-and FOLFIRI-based regimens are common standard of care chemotherapies, and monoclonal antibodies are routinely combined with these chemotherapies. (NSPH 2008(NSPH , 2009) demonstrated that clustering of oncology resources exceeds the spatial concentration pattern of health-care services in Greece, thus resulting to substantial cross-regional fl ows of cancer patients. The objective of this study was to assess the impact of geographic accessibility on patients when selecting care and during treatment for cancer. METHODS: Face-to-face interviews with 106 patients diagnosed with cancer from three specialized anticancer hospitals (two Athens and one Thesaloniki). Questionnaire was designed by a specialized Delphi panel of the NSPH to capture patient preferences. Median patient age was 54.5 years. Data were analyzed using SPSS v.15.0. RESULTS: Patients across the board choose their hospital on the basis of specialization (50%), physician reference (41.5%), and hospital reputation (35.8%). Sixty-three percent of patients face access barriers, most commonly cost of health-care services (44.3%), distance from place of residence (37%), and demand on time (33%). 76.4% of patients return to place of residence at treatment intervals and 43.4% immediately after treatment. To receive treatment, 23.6% stay at homes of relatives, 14.2% at hotels, and 1% in hospital-owned hospices. Fifty percent of patients undergo treatment cycles repeating every 15-30 days. Patients travel predominately by own car (48.1%). 4.7% travel by taxi reimbursed by their insurance fund and 1% by hospital ambulance. 84% of patients travel accompanied by one or more carers. At treatment intervals, only 8% of patients are supported by physicians at place of residence. CONCLUSIONS: Signifi cant cross-regional fl ows of cancer patients to access adequate treatment lead to substantial direct and indirect costs for patients and their carers in a strained fi nancial environment. Patients also face signifi cant gaps in integrated support during treatment intervals. a shift in the organization of cancer services is essential for the system to be responsive to expressed patient needs especially during treatment. Centre Hospitalier Universitaire Brugmann, Brussels, Belgium; 2 Kantonsspital Graubünden, Chur, Switzerland; 3 University of Arizona, Tucson, AZ, USA; 4 Amgen Inc., Thousand Oaks, CA, USA OBJECTIVES: Bone metastases occur in up to 75% of patients with advanced breast cancer. Skeletal complications of bone metastases include pathologic fracture, spinal cord compression, and surgery and radiation to bone. In a recently completed trial of breast cancer patients with bone metastases, denosumab, a fully human monoclonal anti-RANKL antibody, was superior to zoledronic acid (ZA) in delaying/preventing skeletal related events (SRE). METHODS: Eligible patients (N = 1026, denosumab; N = 1020, ZA) received monthly subcutaneous denosumab 120 mg or intravenous ZA 4 mg in a double-bind, double-dummy design. Health resource utilization (HRU) data, excluding protocol-specifi ed visits, were collected from all randomized patients monthly through end of study (median duration 17 months, both groups). RESULTS: Comparing patients who experienced any on-study SRE (n = 315, denosumab; n = 372, ZA) with patients without an on-study SRE, a greater proportion reported at least one radiation oncology unit visit (22.9% vs. 8.7%), clinic visit (75.5% vs. 71.1%), and inpatient hospitalization (62.9% vs. 48.6%). The mean number of clinic visits and inpatient hospitalizations was also greater for patients who experienced an on-study SRE. A between-treatment group comparison of denosumab versus ZA demonstrated that for patients with one or more clinic visits who experienced any on-study SRE, the denosumab group had 10% fewer mean clinic visits compared with the ZA group (15.5 vs. 17.2 visits). Additionally, mean radiation oncology clinic visits were decreased by 32% in the denosumab compared with the ZA group (4.2 vs. 6.2 visits) and mean inpatient hospitalizations were decreased by 12% (3.7 vs. 4.2 hospitalizations). CONCLUSIONS: Regardless of treatment group, patients who had an on-study SRE had greater HRU compared with patients not experiencing an on-study SRE. In this study, among those with any on-study SRE, patients treated with denosumab had fewer clinic visits, radiation oncology unit visits, and inpatient hospitalizations compared to patients treated with zoledronic acid.
PCN145 INEQUALITIES IN GEOGRAPHICAL ACCESS TO ONCOLOGY SERVICES IN GREECE AND THEIR IMPACT ON PATIENTS AND CARERS
Souliotis K 1 , Athanasakis K 2 , Palaka E 3 , Kyriopoulos II 2 , Golna C 4 , Kyriopoulos J 2 1 University of Peloponnese, Corinth, Corinth, Greece; 2 National School of Public Health, Athens, Greece; 3 Foundation of Economic and Industrial Research, Athens, Attica, Greece; 4 Roche Hellas SA, Athens, Greece OBJECTIVES: Previous studies (NSPH 2008 (NSPH , 2009 ) demonstrated that clustering of oncology resources exceeds the spatial concentration pattern of health-care services in Greece, thus resulting to substantial cross-regional fl ows of cancer patients. The objective of this study was to assess the impact of geographic accessibility on patients when selecting care and during treatment for cancer. METHODS: Face-to-face interviews with 106 patients diagnosed with cancer from three specialized anticancer hospitals (two Athens and one Thesaloniki). Questionnaire was designed by a specialized Delphi panel of the NSPH to capture patient preferences. Median patient age was 54.5 years. Data were analyzed using SPSS v.15.0. RESULTS: Patients across the board choose their hospital on the basis of specialization (50%), physician reference (41.5%), and hospital reputation (35.8%). Sixty-three percent of patients face access barriers, most commonly cost of health-care services (44.3%), distance from place of residence (37%), and demand on time (33%). 76.4% of patients return to place of residence at treatment intervals and 43.4% immediately after treatment. To receive treatment, 23.6% stay at homes of relatives, 14.2% at hotels, and 1% in hospital-owned hospices. Fifty percent of patients undergo treatment cycles repeating every 15-30 days. Patients travel predominately by own car (48.1%). 4.7% travel by taxi reimbursed by their insurance fund and 1% by hospital ambulance. 84% of patients travel accompanied by one or more carers. At treatment intervals, only 8% of patients are supported by physicians at place of residence. CONCLUSIONS: Signifi cant cross-regional fl ows of cancer patients to access adequate treatment lead to substantial direct and indirect costs for patients and their carers in a strained fi nancial environment. Patients also face signifi cant gaps in integrated support during treatment intervals. a shift in the organization of cancer services is essential for the system to be responsive to expressed patient needs especially during treatment. Centre Hospitalier Universitaire Brugmann, Brussels, Belgium; 2 Kantonsspital Graubünden, Chur, Switzerland; 3 University of Arizona, Tucson, AZ, USA; 4 Amgen Inc., Thousand Oaks, CA, USA OBJECTIVES: Bone metastases occur in up to 75% of patients with advanced breast cancer. Skeletal complications of bone metastases include pathologic fracture, spinal cord compression, and surgery and radiation to bone. In a recently completed trial of breast cancer patients with bone metastases, denosumab, a fully human monoclonal anti-RANKL antibody, was superior to zoledronic acid (ZA) in delaying/preventing skeletal related events (SRE). METHODS: Eligible patients (N = 1026, denosumab; N = 1020, ZA) received monthly subcutaneous denosumab 120 mg or intravenous ZA 4 mg in a double-bind, double-dummy design. Health resource utilization (HRU) data, excluding protocol-specifi ed visits, were collected from all randomized patients monthly through end of study (median duration 17 months, both groups). RESULTS: Comparing patients who experienced any on-study SRE (n = 315, denosumab; n = 372, ZA) with patients without an on-study SRE, a greater proportion reported at least one radiation oncology unit visit (22.9% vs. 8.7%), clinic visit (75.5% vs. 71.1%), and inpatient hospitalization (62.9% vs. 48.6%). The mean number of clinic visits and inpatient hospitalizations was also greater for patients who experienced an on-study SRE. A between-treatment group comparison of denosumab versus ZA demonstrated that for patients with one or more clinic visits who experienced any on-study SRE, the denosumab group had 10% fewer mean clinic visits compared with the ZA group (15.5 vs. 17.2 visits). Additionally, mean radiation oncology clinic visits were decreased by 32% in the denosumab compared with the ZA group (4.2 vs. 6.2 visits) and mean inpatient hospitalizations were decreased by 12% (3.7 vs. 4.2 hospitalizations). CONCLUSIONS: Regardless of treatment group, patients who had an on-study SRE had greater HRU compared with patients not experiencing an on-study SRE. In this study, among those with any on-study SRE, patients treated with denosumab had fewer clinic visits, radiation oncology unit visits, and inpatient hospitalizations compared to patients treated with zoledronic acid.
PCN146 HEALTH RESOURCE UTILIZATION OF SUBJECTS RECEIVING DENOSUMAB AND ZOLEDRONIC ACID IN A RANDOMIZED PHASE 3 TRIAL OF ADVANCED BREAST CANCER PATIENTS WITH BONE METASTASES

PCN147 MEDICAL RESOURCES UTILIZATION OF FIVE MOST PREVALENT CANCERS IN TAIWAN (LUNG CANCER, LIVER CANCER, COLORECTAL CANCER, GASTRIC CANCER, AND BREST CANCER): 2001~2007
Liu JS, Chen LT, Hsiao CF National Health Research Institutes, Miaoli County, Taiwan OBJECTIVES: We want to study the real cost structure of cancer treatment using the National Health Insurance Research Database (NHIRD) from Taiwan. METHODS: This study adopted a retrospective observational design and the data were retrieved from the NHIRD, which is managed by the National Health Research Institutes (NHRI). We used descriptive statistical methods to display data and time trend. RESULTS: The number of patients with these fi ve cancers showed an increasing trend in these 7 years. Breast cancer had the highest annual increase (7.34%), followed by colorectal cancer (3.75%). Lung cancer and breast cancer had the highest average outpatient cost for each patient per year, while lung cancer, colorectal cancer, and gastric cancer had the highest average inpatient cost for each patient per year. The annual increase rates in the total cancer treatment cost for liver cancer, lung cancer, colorectal cancer, gastric cancer, and breast cancer were 10.70%, 11.61%, 16.73%, 18.38%, and 17.21% respectively. We divided the cost structure of cancer treatments into chemotherapy, hormone therapy, and supportive treatment. The highest percentages of chemotherapy and hormone therapy were for colorectal cancer (more than 95%) and for breast cancer (more than 11%). On average, the annual increase rates in the cancer chemotherapy cost per patient for liver cancer, lung cancer, colorectal cancer, gastric cancer, and breast cancer were respectively 3.59%, 3.66%, 9.86%, 16.78%, and 11.72%. CONCLUSIONS: This study showed a positive correlation between annual cancer patient number and NHI reimbursement, and an increasing trend for chemotherapy, hormone therapy, and supportive treatment. The results also showed that the number of the total amount of NHI reimbursement and the drug costs had increasing trends in these 7 years. This increased the fi nancial burden of cancer patients and may alter the allocation of NHI resources.
PCN148 IMAGING TESTS IN STAGING AND SURVEILLANCE OF EARLY BREAST CANCER (EBC) IN ITALY-CHANGES IN ROUTINE CLINICAL PRACTICE AND COSTS IMPLICATIONS
Cammarota S 1 , Menditto E 1 , Citarella A 1 , Putignano D 1 , Riegler S 1 , Arpino G 2 1 CIRFF, Federico II University, Naples, Italy;, 2 Federico II University Hospital School of Medicine, Naples, Italy OBJECTIVES: New imaging tests such as computed tomography (CT), [18F]fl uorodeoxyglucose-positron emission tomography (FDG-PET) scanning, and magnetic resonance imaging (MRI) are not recommended for staging or follow-up of asymptomatic patients with EBC according to current guidelines. However, frequently these tests are requested even in the absence of a clinical indication. The purpose of this study was to evaluate how the availability of new imaging techniques has changed staging and follow-up modalities in EBC patients and to estimate its cost implications. METHODS: We analyzed clinical computerized information from 457 general practitioners assisting an average of 630,000 inhabitants of the Campania region in the south of Italy. Incident EBC cases were selected and divided into calendar years from 2005 to 2008. The mean number of diagnostic tests prescribed per patient (N/Pt) and the mean costs per patient were evaluated during the fi rst post-diagnosis year. The mean was compared between each year using one-way analysis of variance. Costs were expressed in Euros (mean ± SD). RESULTS: We identifi ed 576, 489, 474, and 497 newly diagnosed cases of EBC in 2005 EBC in , 2006 EBC in , 2007 EBC in , and 2008 , respectively. Overall, there was a signifi cant increase of the mean number of imaging tests prescribed per patient from 2005 to 2008 (P < 0.0001). No change of the mean number of mammograms, bone scan, and chest x-ray requested per patient was observed. The mean costs per patient also signifi cantly increased from c354.96 ± 581.32 in 2005 to c546.78 ± 837.36 in 2008 (P = 0.004). CONCLUSIONS: CT, FDG-PET, and MRI employment for EBC patients in daily clinical practice has been steadily growing over the past 4 years with cost repercussions. However, there are no data to support their role in routine breast
